Roche Cobas HPV Self Sampling Solution
Roche has launched a human papillomavirus self-collection solution in countries accepting the CE mark. The new sample type falls under the Cobas HPV test's original CE marking in 2017, Roche said. The solution allows patients to collect their own vaginal samples in a healthcare facility following instructions from a healthcare worker and is intended to provide an alternative to more invasive clinician collection procedures.
The Cobas HPV test is indicated for use for routine cervical cancer screening, including HPV primary screening, co-testing with cytology, and for triage of women with abnormal cytology. The test runs on the fully automated Cobas 6800/8800 instrument.